A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
Public ClinicalTrials.gov record NCT02040779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a Breath-Actuated Inhaler (BAI); or a matching BAI placebo, in a 1:1:1 ratio after a 14- to 21-day run-in period. Participants and investigators will remain blinded to randomized treatment assignment during the study
Study identification
- NCT ID
- NCT02040779
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 273 participants
Conditions and interventions
Conditions
Interventions
- Beclomethasone dipropionate breath-actuated inhaler Drug
- Placebo breath-actuated inhaler Drug
- albuterol/salbutamol Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 25, 2013
- Primary completion
- Dec 23, 2014
- Completion
- Dec 23, 2014
- Last update posted
- Nov 8, 2021
2013 – 2014
United States locations
- U.S. sites
- 47
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12813 | Huntington Beach | California | — | — |
| Teva Investigational Site 10944 | Mission Viejo | California | — | — |
| Teva Investigational Site 10946 | Orange | California | — | — |
| Teva Investigational Site 10963 | Rolling Hills Estates | California | — | — |
| Teva Investigational Site 10960 | San Diego | California | — | — |
| Teva Investigational Site 10973 | San Diego | California | — | — |
| Teva Investigational Site 10975 | San Jose | California | — | — |
| Teva Investigational Site 10948 | Centennial | Colorado | — | — |
| Teva Investigational Site 10958 | Centennial | Colorado | — | — |
| Teva Investigational Site 10957 | Colorado Springs | Colorado | — | — |
| Teva Investigational Site 12814 | Sarasota | Florida | — | — |
| Teva Investigational Site 10962 | Tallahassee | Florida | — | — |
| Teva Investigational Site 12809 | Savannah | Georgia | — | — |
| Teva Investigational Site 10947 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 10943 | Iowa City | Iowa | — | — |
| Teva Investigational Site 10954 | Baltimore | Maryland | — | — |
| Teva Investigational Site 12940 | Bethesda | Maryland | — | — |
| Teva Investigational Site 10955 | North Dartmouth | Massachusetts | — | — |
| Teva Investigational Site 10941 | Minneapolis | Minnesota | — | — |
| Teva Investigational Site 10970 | Columbia | Missouri | — | — |
| Teva Investigational Site 10968 | Rolla | Missouri | — | — |
| Teva Investigational Site 10972 | Bozeman | Montana | — | — |
| Teva Investigational Site 12941 | Missoula | Montana | — | — |
| Teva Investigational Site 10942 | Bellevue | Nebraska | — | — |
| Teva Investigational Site 10959 | Skillman | New Jersey | — | — |
| Teva Investigational Site 10945 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 12810 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 10974 | Sylvania | Ohio | — | — |
| Teva Investigational Site 12805 | Oklahoma City | Oklahoma | — | — |
| Teva Investigational Site 12942 | Oklahoma City | Oklahoma | — | — |
| Teva Investigational Site 10951 | Tulsa | Oklahoma | — | — |
| Teva Investigational Site 10940 | Lake Oswego | Oregon | — | — |
| Teva Investigational Site 10952 | Medford | Oregon | — | — |
| Teva Investigational Site 10956 | Portland | Oregon | — | — |
| Teva Investigational Site 12939 | Pittsburgh | Pennsylvania | — | — |
| Teva Investigational Site 12806 | Orangeburg | South Carolina | — | — |
| Teva Investigational Site 12811 | Knoxville | Tennessee | — | — |
| Teva Investigational Site 10969 | Austin | Texas | — | — |
| Teva Investigational Site 12812 | Boerne | Texas | — | — |
| Teva Investigational Site 10949 | Dallas | Texas | — | — |
| Teva Investigational Site 10953 | El Paso | Texas | — | — |
| Teva Investigational Site 12807 | Houston | Texas | — | — |
| Teva Investigational Site 10950 | New Braunfels | Texas | — | — |
| Teva Investigational Site 10961 | San Antonio | Texas | — | — |
| Teva Investigational Site 12808 | Waco | Texas | — | — |
| Teva Investigational Site 10967 | Seattle | Washington | — | — |
| Teva Investigational Site 10964 | Greenfield | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02040779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2021 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02040779 live on ClinicalTrials.gov.